Interferon als adjuvante therapie bij het melanoom: wel geregistreerd, niet geïndiceerd

G. Groenewegen, S. Osanto, H. J. van der Rhee, C. J. Punt

Research output: Contribution to JournalArticleProfessional

7 Citations (Scopus)

Abstract

The Dutch melanoma group reconsidered their 1997 consensus statement on treatment of melanoma because new studies on adjuvant treatment with interferon(IFN)-alpha have been published. These have resulted in its registration for stage IIa; for stage IIb/III IFN-alpha was already registered. Overall survival should be the main endpoint of adjuvant clinical studies, especially when treatment is associated with toxicity. Since a benefit has not been unequivocally demonstrated in melanoma with Breslow thickness > 1.5 mm and/or regional lymph node metastases, there is no need to change the Dutch consensus statement. Drug registration authorities and medical professionals should cooperate more closely
Original languageDutch
Pages (from-to)2160-2162
JournalNederlands Tijdschrift voor Geneeskunde
Volume144
Issue number45
Publication statusPublished - 2000

Cite this